Octis Research Laboratories Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 27-12-2024
- Paid Up Capital ₹ 7.50 M
as on 27-12-2024
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2018
- Satisfied Charges ₹ 2.50 M
as on 27-12-2024
- Revenue -86.49%
(FY 2018)
- Profit 86.14%
(FY 2018)
- Ebitda -550.78%
(FY 2018)
- Net Worth -2.64%
(FY 2018)
- Total Assets -12.11%
(FY 2018)
About Octis Research Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.50 M.
The company has closed loans amounting to ₹2.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ravichandran Rajappa and Venugopal Thangaraj serve as directors at the Company.
- CIN/LLPIN
U01117TN2006PTC059437
- Company No.
059437
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Apr 2006
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Octis Research Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravichandran Rajappa  | Managing Director | 05-Apr-2006 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venugopal Thangaraj | Director | 22-Apr-2006 | Current |
Financial Performance of Octis Research Laboratories.
Octis Research Laboratories Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 86.49% decrease. The company also saw a substantial improvement in profitability, with a 86.14% increase in profit. The company's net worth dipped by a decrease of 2.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Octis Research Laboratories?
In 2018, Octis Research Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ishaanav Nutraceuticals Private LimitedActive 8 years 2 monthsVenugopal Thangaraj is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 14 Aug 2007 | ₹2.50 M | Satisfied |
How Many Employees Work at Octis Research Laboratories?
Unlock and access historical data on people associated with Octis Research Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Octis Research Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Octis Research Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
